John L.P. Thompson

7.0k total citations · 1 hit paper
96 papers, 3.6k citations indexed

About

John L.P. Thompson is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, John L.P. Thompson has authored 96 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Cardiology and Cardiovascular Medicine, 20 papers in Molecular Biology and 15 papers in Epidemiology. Recurrent topics in John L.P. Thompson's work include Atrial Fibrillation Management and Outcomes (19 papers), Acute Ischemic Stroke Management (14 papers) and Heart Failure Treatment and Management (12 papers). John L.P. Thompson is often cited by papers focused on Atrial Fibrillation Management and Outcomes (19 papers), Acute Ischemic Stroke Management (14 papers) and Heart Failure Treatment and Management (12 papers). John L.P. Thompson collaborates with scholars based in United States, United Kingdom and Netherlands. John L.P. Thompson's co-authors include J.P. Mohr, Ralph L. Sacco, Bruce Lubotsky Levin, Patrick Pullicino, Ronald M. Lazar, Karen L. Furie, J. Philip Kistler, Gregory W. Albers, Harold P. Adams and L. Creed Pettigrew and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and JAMA.

In The Last Decade

John L.P. Thompson

93 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke

2001 749 citations J.P. Mohr, John L.P. Thompson et al. profile →

Peers

Countries citing papers authored by John L.P. Thompson

Since Specialization

Citations

This map shows the geographic impact of John L.P. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L.P. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L.P. Thompson more than expected).

Fields of papers citing papers by John L.P. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L.P. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L.P. Thompson. The network helps show where John L.P. Thompson may publish in the future.

Co-authorship network of co-authors of John L.P. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of John L.P. Thompson. A scholar is included among the top collaborators of John L.P. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L.P. Thompson. John L.P. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Educational status affects prognosis of patients with heart failure with reduced ejection fraction: A post‐hoc analysis from the WARCEF trial	European Journal of Clinical Investigation	Bernadette Corica, Giulio Francesco Romiti et al.	3
2	The evolution of the mitochondrial disease diagnostic odyssey	Orphanet Journal of Rare Diseases	John L.P. Thompson, Amel Karaa et al.	6
3	Machine Learning Predicting Atrial Fibrillation as an Adverse Event in the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial	The American Journal of Medicine	Ying X. Gue, Elon Correa et al.	5
4	Educational level and risk of all-cause death in patients with heart failure with reduced ejection fraction (HFrEF): a report from the WARCEF Trial	European Heart Journal	Bernadette Corica, Giulio Francesco Romiti et al.	0
5	The North American mitochondrial disease registry	PubMed	Xiomara Q. Rosales, John L.P. Thompson et al.	5
6	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction	European Journal of Clinical Investigation	Neeraj Shah, Min Qian et al.	1
7	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients	JACC Heart Failure	John R. Teerlink, Min Qian et al.	2
8	Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy	Human Reproduction	Kristin Engelstad, Miriam Sklerov et al.	14
9	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure　– Subanalysis of the WARCEF Trial –	Circulation Journal	Tomoko S. Kato, Marco R. Di Tullio et al.	8
10	The first prognostic model for stroke and death in patients with systolic heart failure	Journal of Cardiology	Ronald S. Freudenberger, Bin Cheng et al.	15
11	COGNITIVE FUNCTION IN AMBULATORY PATIENTS WITH SYSTOLIC HEART FAILURE: INSIGHTS FROM THE WARFARIN VERSUS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION (WARCEF) TRIAL	Journal of the American College of Cardiology	Siqin Ye, Susan Graham et al.	2
12	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial	Cerebrovascular Diseases	Patrick M. Pullicino, Min Qian et al.	24
13	Amino Terminal Pro–B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy	Stroke	W. T. Longstreth, Richard A. Kronmal et al.	79
14	Body Mass Index (BMI) as Predictor of ALSFRS-r Score Decline in ALS Patients (P07.085)	Neurology	Ronit Reich‐Slotky, Jinsy Andrews et al.	1
15	Web-based data management for a phase II clinical trial in ALS	Amyotrophic Lateral Sclerosis	Richard Buchsbaum, Petra Kaufmann et al.	9
16	Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial	Amyotrophic Lateral Sclerosis	Petra Kaufmann, Alexandra I. Barsdorf et al.	100
17	Warfarin Versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): Rationale, Objectives, and Design	Journal of Cardiac Failure	Patrick Pullicino, John L.P. Thompson et al.	74
18	Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients	Cancer Forum	Richard A. Scolyer, Jonathan R. Stretch et al.	8
19	Frequency and Determinants of Microembolic Signals on Transcranial Doppler in Unselected Patients with Acute Carotid Territory Ischemia	Cerebrovascular Diseases	Henning Mast, Ralph L. Sacco et al.	35
20	Inter-rater reliability of the modified Ashworth Scale for spasticity in hemiplegic patients	International Journal of Rehabilitation Research	Emma Sinclair, John L.P. Thompson et al.	118

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact